142 related articles for article (PubMed ID: 21996974)
21. [Sorafenib in the treatment of hepatocellular carcinoma].
Suchánková G; Spicák J
Vnitr Lek; 2011 May; 57(5):485-90. PubMed ID: 21695929
[TBL] [Abstract][Full Text] [Related]
22. [Use of sorafenib in patients with hepatocellular or renal carcinoma].
Rosmorduc O; Chevreau C; Dielenseger P; Ederhy S; Goldwasser F; Grange JD; Mortier L; Neidhardt-Berard ME; Robert C; Scotté F; Seitz JF
Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452
[TBL] [Abstract][Full Text] [Related]
23. Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report.
Shiozawa K; Watanabe M; Takenaka H; Nagai H; Ishii K; Sakai K; Sumino Y
Hepatogastroenterology; 2010; 57(101):688-90. PubMed ID: 21033210
[TBL] [Abstract][Full Text] [Related]
24. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
Zhu AX; Clark JW
Oncologist; 2009 Jan; 14(1):67-9. PubMed ID: 19147690
[No Abstract] [Full Text] [Related]
25. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
Greten TF; Manns MP; Malek N
Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.
van Doorn L; Eskens FA; Visser TJ; van der Lugt A; Mathijssen RH; Peeters RP
Thyroid; 2011 Feb; 21(2):197-202. PubMed ID: 21275767
[TBL] [Abstract][Full Text] [Related]
27. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
[TBL] [Abstract][Full Text] [Related]
28. [Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib].
Takeda Y; Nakahira S; Takeno A; Suzuki R; Nakata K; Okishiro M; Egawa C; Okamura S; Miki H; Kato T; Takatsuka Y; Tamura S
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2496-8. PubMed ID: 22202425
[TBL] [Abstract][Full Text] [Related]
29. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C
Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401
[TBL] [Abstract][Full Text] [Related]
30. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma.
Hsieh CH; Jeng KS; Lin CC; Chen CK; Liu CY; Lin CP; Tai HC; Wang CH; Shueng PW; Chen YJ
Clin Drug Investig; 2009; 29(1):65-71. PubMed ID: 19067476
[TBL] [Abstract][Full Text] [Related]
31. Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation.
Mancuso A; Airoldi A; Vigano R; Pinzello G
Dig Liver Dis; 2011 Sep; 43(9):754. PubMed ID: 21641889
[No Abstract] [Full Text] [Related]
32. Hepatocellular carcinoma: sorafenib before liver transplantation?
Braillon A
Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
[No Abstract] [Full Text] [Related]
33. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
Schütte K; Zimmermann L; Bornschein J; Csepregi A; Rühl R; Ricke J; Malfertheiner P
Digestion; 2011; 83(4):275-82. PubMed ID: 21282952
[TBL] [Abstract][Full Text] [Related]
34. [Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis].
Duan F; Wang MQ; Liu FY; Wang ZJ; Song P
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):716-8. PubMed ID: 20021873
[TBL] [Abstract][Full Text] [Related]
35. Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.
Kim SO; Han SY; Baek YH; Lee SW; Han JS; Kim BG; Cho JH; Nam KJ
World J Gastroenterol; 2011 Jan; 17(2):267-70. PubMed ID: 21246003
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
37. Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma.
Diaz-Sanchez A; Rodriguez-Salas N; Aramendi T; Balbin E
Dig Liver Dis; 2011 Apr; 43(4):333-4. PubMed ID: 21215716
[No Abstract] [Full Text] [Related]
38. Sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up.
Di Benedetto F; Tarantino G; Montalti R; Ballarin R; D'Amico G; Berretta M; Gerunda GE
Transpl Int; 2011 Nov; 24(11):e97; author reply e98-9. PubMed ID: 21910763
[No Abstract] [Full Text] [Related]
39. Sorafenib: in hepatocellular carcinoma.
Simpson D; Keating GM
Drugs; 2008; 68(2):251-8. PubMed ID: 18197728
[TBL] [Abstract][Full Text] [Related]
40. [Influence of body surface area on efficacy and safety of sorafenib in advanced hepatocellular carcinoma].
Kobayashi S; Ohkawa S; Kondo M; Morimoto M; Numata K; Matsunaga K; Okuse C; Suzuki M; Hidaka H; Takada J; Okuwaki Y; Shibuya A; Tanaka K
Gan To Kagaku Ryoho; 2012 Jul; 39(7):1065-70. PubMed ID: 22790040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
